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Preamble
Since the 1995 publication of its Core Cardiovascular Training 
Statement (COCATS),1 the American College of Cardiology 
(ACC) has played a central role in defining the knowledge, 
experiences, skills, and behaviors expected of all clinical car-
diologists upon completion of training. Subsequent updates 
have incorporated major advances and revisions—both in 
content and structure—including, most recently, a further 
move toward competency (outcomes)-based training, and the 
use of the 6-domain competency structure promulgated by 
the Accreditation Council for Graduate Medical Education 
(ACGME) and the American Board of Medical Specialties 
and endorsed by the American Board of Internal Medicine 
(ABIM). A similar structure has been used by the ACC to 
describe the aligned general cardiology lifelong learning 
competencies that all practicing cardiologists are expected to 
maintain. Many hospital systems also now use the 6-domain 
structure as part of medical staff privileging and peer-review 
professional competence assessments.
Whereas COCATS has focused on general clinical cardiol-
ogy, ACC Advanced Training Statements define selected com-
petencies that go beyond those expected of all cardiologists 
and require training beyond a standard 3-year cardiovascular 
disease fellowship. This includes sub-subspecialties for which 
there is an ABIM added-qualification designation, such as 
advanced heart failure and transplant cardiology (AHFTC). 
The Advanced Training Statements also describe key expe-
riences and outcomes necessary to maintain or expand com-
petencies during practice, although over time, these will be 
supplemented by additional lifelong learning statements that 
address the commitment to sustaining and enriching compe-
tency over the span of a career.
The ACC Competency Management Committee oversees 
the development and periodic revision of the cardiovascu-
lar training and competency statements. A key feature of 
competency-based training and performance is an outcomes-
based evaluation system. Although specific areas of training 
may require a minimum number of procedures or duration 
of training time to ensure adequate exposure to the range 
of clinical disorders and to effectively evaluate the trainee, 
it is the objective assessment of proficiency and outcomes 
that demonstrates the trainee’s achievement of competency. 
Evaluation tools may include in-training examinations, 
direct observation, procedure logbooks, simulation, con-
ference presentations, and multisource (360°) evaluations, 
among others. For practicing physicians, these tools may 
also include professional society registry or hospital quality 
data, peer-review processes, and patient satisfaction surveys. 
A second feature of a competency-based training program is 
the recognition that learners develop some competency com-
ponents at different rates. For multiyear training programs, 
assessment of selected representative curricular milestones 
during training can identify learners or areas that require 
additional focused attention.
The recommendations in the ACC cardiovascular training 
statements are based on available evidence and, where evi-
dence is lacking, reflect expert opinion. The writing commit-
tees are broad-based, and typically include content experts, 
general cardiology and sub-subspecialty training directors, 
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practicing cardiologists, and early-career representatives. All 
documents go through a rigorous process of peer-review and 
public comment. Recommendations are intended to guide 
the assessment of competence of cardiovascular care provid-
ers who are beginning independent practice as well as those 
undergoing periodic review to help ensure that competence is 
maintained.
This Advanced Training Statement addresses the added 
competencies required of sub-subspecialists in AHFTC for 
diagnosis and management at a high level of skill of patients 
with advanced heart failure who may also undergo placement 
of mechanical circulatory support devices or cardiac trans-
plantation. It is intended to complement the basic training in 
heart failure required of all trainees during the standard 3-year 
cardiovascular fellowship. The training requirements and des-
ignated clinical competencies in this report focus on the core 
competencies reasonably expected of all AHFTC specialists. 
It also identifies some aspects of AHFTC that go beyond the 
core expectations and that may be achieved by some AHFTC 
specialists based on career focus, either during or following 
formal AHFTC fellowship training.
The work of the writing committee was supported exclu-
sively by the ACC without commercial support. Writing 
committee members volunteered their time to this effort. 
Conference calls of the writing committee were confidential 
and attended only by committee members. To avoid actual, 
potential, or perceived conflict of interest arising as a result 
of relationships with industry (RWI) or other entities, each 
member of the writing committee and peer reviewer of the 
document is required to disclose all current healthcare-related 
relationships, including those existing 12 months before initia-
tion of the writing effort. The ACC Competency Management 
Committee reviewed these disclosures to identify products 
(marketed or under development) pertinent to the document 
topic. Based on this information, the writing committee was 
selected to ensure that the Chair and a majority of members 
have no relevant RWI. Authors with relevant RWI were not 
permitted to draft initial text or vote on recommendations 
or curricular requirements to which their RWI might apply. 
RWI was reviewed at the start of all meetings and confer-
ence calls and updated as changes occurred. Relevant RWI 
for authors is disclosed in Appendix 1. To ensure transpar-
ency, comprehensive RWI for authors, including RWI not 
pertinent to this document, is available as Data Supplement 
1. Peer reviewers, along with their employment information 
and affiliation in the review process, are shown in Appendix 2. 
There are no RWI restrictions for participation in peer review, 
promoting the opportunity for comment on the document 
from a variety of constituencies/viewpoints to inform final 
document content. However, all reviewers must disclose all 
healthcare-related RWI and other entities to participate in the 
review process, and their disclosure information is available 
as Data Supplement 2. Disclosure information for the ACC 
Competency Management Committee is also available online, 
as is the ACC disclosure policy for document development.
Eric S. Williams, MD, MACC
Chair, ACC Competency Management Committee
Jonathan L. Halperin, MD, FACC
Co-Chair, ACC Competency Management Committee
1. Introduction
1.1. Document Development Process
1.1.1. Writing Committee Organization
The writing committee consisted of a broad range of mem-
bers representing the ACC, the American Heart Association 
(AHA), the Heart Failure Society of America, the International 
Society for Heart & Lung Transplantation, and the American 
College of Physicians, identified because they perform >=1 
of the following roles: cardiovascular training program direc-
tors; AHFTC training program directors; early-career experts 
through mid- and later-career experts; general cardiologists; 
AHFTC specialists representing both the academic and com-
munity-based practice settings as well as small, medium, 
and large institutions; specialists in all aspects of AHFTC, 
including mechanical circulatory support (MCS), cardiac 
resynchronization therapy, and pulmonary arterial hyperten-
sion; specialists in cardiothoracic surgery, critical care cardi-
ology, electrophysiology, and adult congenital heart disease; 
physicians experienced in training and working with the 
ACGME/Residency Review Committee as well as the ABIM 
Cardiovascular Board and Competency Committee; physi-
cians experienced in defining and applying training standards 
according to the 6 general competency domains promul-
gated by the ACGME and the American Board of Medical 
Specialties and endorsed by the ABIM; and advanced practice 
nurses. This writing committee met the College’s disclosure 
requirements for RWI as described in the Preamble.
1.1.2. Document Development and Approval
The writing committee convened by conference call and 
e-mail to finalize the document outline, develop the initial 
draft, revise the draft based on committee feedback, and ulti-
mately approve the document for external peer review.
The document was reviewed by 11 official representa-
tives from the ACC, AHA, Heart Failure Society of America, 
International Society for Heart & Lung Transplantation, and 
American College of Physicians, as well as by 35 additional 
content reviewers, including AHFTC training program direc-
tors (Appendix 2). The document was simultaneously posted 
for public comment from November 1, 2016, to November 
18, 2016, resulting in comments from 6 additional reviewers. 
A total of 445 comments were submitted on the document. 
All comments were reviewed and addressed by the writing 
committee. A member of the ACC Competency Management 
Committee served as lead reviewer to ensure a fair and bal-
anced peer review resolution process. Both the writing com-
mittee and the ACC Competency Management Committee 
approved the final document to be sent for organizational 
approval. The ACC, AHA, Heart Failure Society of America, 
International Society for Heart & Lung Transplantation, and 
American College of Physicians approved the document for 
publication. This document is considered current until the 
ACC Competency Management Committee revises or with-
draws it from publication.
1.2. Background and Scope
The original 1995 American College of Cardiology recom-
mendations for training in adult cardiology evolved from 
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COCATS.1 After several iterations, COCATS 4 focuses on 
trainee outcomes that require delineation of specific compo-
nents of competency within the subspecialty, definition of the 
tools necessary to assess training, and establishment of mile-
stones documenting the trainee’s progression toward indepen-
dent competency.2 Ultimately, the goal is for the trainee to 
develop the professional skillset to be able to evaluate, diag-
nose, and treat patients with acute and chronic cardiovascular 
disturbances.
Each COCATS 4 document includes individual task force 
reports that address subspecialty areas in cardiology, each of 
which is an important component in training a fellow in car-
diovascular disease. Task Force 12 of that document addresses 
training in heart failure and updated previous standards for 
general cardiovascular training for fellows enrolled in cardio-
vascular fellowship programs.3 It addresses faculty, facilities, 
equipment, and ancillary support. It also addresses training 
components, including didactic, clinical, and hands-on expe-
rience, and the number of procedures and duration of training. 
Importantly, the COCATS 4 Task Force 12 report did not pro-
vide specific guidelines for AHFTC training.
This document focuses on training requirements for cardi-
ologists seeking additional training in AHFTC, a subspecialty 
of adult cardiology. For training standards related to pediat-
ric heart failure, readers should refer to the SPCTPD/ACC/
AAP/AHA Training Guidelines for Pediatric Cardiology 
Fellowship Programs Task Force 7: Pediatric Cardiology 
Fellowship Training in Pulmonary Hypertension, Advanced 
Heart Failure, and Transplantation.4
1.2.1. Evolution of AHFTC
In 2008, the American Board of Medical Specialties approved 
a proposal by the ABIM to recognize the secondary subspe-
cialty of AHFTC. The ACGME approved the training program 
requirements for AHFTC, effective in 2013. These actions 
acknowledged the special competencies, knowledge, and 
skills required to care for patients with advanced heart fail-
ure, including the possible use of ventricular assist devices or 
cardiac transplantation. Over subsequent years, an increasing 
number of cardiologists have chosen to focus their research 
and/or clinical practice in this area.
The ABIM requires 3 years of cardiology fellowship 
training before fellows may sit for the certification exami-
nation in cardiovascular medicine. Cardiologists seeking 
additional certification in AHFTC must complete a 4th year 
of training that provides focused experience with a variety 
of heart failure patients and procedures, as outlined in the 
following text.
1.2.2. Levels of Training
COCATS 4 updated standards for training fellows in cardio-
vascular medicine and established consistent training criteria 
across all aspects of general cardiology, including heart fail-
ure.3 For the cardiovascular fellowship, the following 3 levels 
of training are delineated for training in heart failure.
•  Level I training, the basic training required of train-
ees to become competent consultant cardiologists, is 
required of all fellows in cardiology, and can be accom-
plished as part of a standard 3-year training program in 
general cardiology.
•  Level II training, also described in COCATS 4, refers 
to additional training that enables some cardiologists to 
perform or interpret specific procedures or render more 
specialized care for patients with certain conditions. 
Level II training in selected areas may be achieved by 
some trainees during the standard 3-year cardiovascu-
lar fellowship, depending on their career goals and use 
of elective rotations. In the case of heart failure, Level 
II training is intended for individuals seeking expertise 
in caring for heart failure patients, particularly those 
with more advanced and challenging syndromes. Level 
II emphasizes more detailed hemodynamic assessment 
of these patients and focuses on transitions of care for 
patients with heart failure as well as the systems of care 
necessary to avoid hospital admission or readmission. 
Level II training also prepares individuals to perform 
initial screening of patients cared for at nontransplant/
nondurable MCS facilities for advanced therapies, in 
collaboration with Level III–trained experts at advanced 
therapy sites.
•  Level III training, the primary focus of this document, 
requires training and experience beyond the cardio-
vascular fellowship for the acquisition of specialized 
knowledge and competency to render advanced care 
for patients with specific conditions. Level III train-
ing is required of individuals seeking subspecialty 
board certification in AHFTC. Trainees in AHFTC are 
expected to have completed 3 years of a cardiovas-
cular fellowship and achieved Level I competency as 
described in the ACC’s Core Cardiovascular Training 
Statement2 and the COCATS 4 Task Force 12 report3 
before beginning the AHFTC fellowship. Level II 
training may be completed prior to or in conjunction 
with Level III training.
1.2.3. Methods for Determining Procedural Numbers
The recommended number of procedures performed and 
interpreted by trainees under faculty supervision has been 
developed based on the experience and opinions of the mem-
bers of the writing group; previously published competency 
statements and COCATS documents; and policies of the 
ACGME, ABIM, and United Network for Organ Sharing. 
In addition, the writing committee surveyed AHFTC train-
ing program directors for additional insight into procedural 
volumes. Of 69 directors of ABIM–recognized training pro-
grams, 21 responded. The procedural volumes and number 
of technical experiences suggested in this document were 
considered the minimum necessary to expose trainees to 
a sufficient range and complexity of clinical material and 
allow supervising faculty to evaluate the competency of 
each trainee. These procedural numbers (see Section 4.2) 
are intended as general guidance, based on the needs and 
progress of typical AHFTC trainees in typical programs. 
Those considering these thresholds should bear in mind the 
fundamental nature of educational milestones—that profi-
ciency and outcomes, rather than length of exposure or the 
exact number of procedures performed, are the dominant 
requirements. Flexibility is inherent to this concept, and the 
ACGME mandates that all programs establish milestones for 
the acquisition of various competencies by trainees during 
the course of fellowship training.
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2. General Standards
2.1. Faculty
Engaged faculty committed to teaching are critical to the suc-
cess of an AHFTC training program. Faculty must include 
specialists with broad knowledge of and experience in 
advanced heart failure, including advanced therapies and end-
of-life care; management of patients with temporary and dura-
ble MCS devices and their complications; and care of heart 
transplant recipients, including management of acute and 
long-term complications. The most recent ACGME Program 
Requirements for Graduate Medical Education in AHFTC 
require a single designated program director and at least 1 
additional key clinical faculty member for every 1.5 fellows.5 
Each of the key clinical faculty members should be currently 
certified in AHFTC by the ABIM and be able to dedicate, on 
average, 10 hours per week throughout the year to the edu-
cational program. In addition to developing, implementing, 
supervising, mentoring, and evaluating the fellows’ clinical 
and research education, at least 50% of key clinical faculty 
members must also demonstrate productivity in scholarship, 
specifically, peer-reviewed funding and/or publication of 
original research, reviews, editorials, case reports, or textbook 
chapters.
2.2. Facilities
Required facilities include designated areas for outpatient and 
inpatient care of patients with heart failure. Inpatient facili-
ties must provide a safe and effective environment for optimal 
management of patients with heart failure of varying severity, 
ranging from mild decompensation to refractory cardiogenic 
shock. A safe and sterile catheterization laboratory is neces-
sary to provide instruction in right heart catheterization and 
endomyocardial biopsy. Trainees should have access to operat-
ing rooms and staff to enable observation of ventricular assist 
device implants, heart procurements, and transplant surgeries. 
Trainees should have access to outpatient facilities supported 
by dedicated nursing staff providing exposure to coordinated 
longitudinal management of patients with chronic heart fail-
ure as well as training in the consultative aspects of outpa-
tient heart failure cardiology. There should be an established 
system to promote effective transitions of care that ensures 
open communication between caregivers in the outpatient and 
inpatient settings. Access to an HLA laboratory should be 
provided. Appropriate space for didactic conferences should 
be available. Quality and safety initiatives should be in place 
to assess quality of care and clinical outcomes longitudinally 
across inpatient and outpatient arenas throughout the health-
care system.
2.3. Equipment
Cardiopulmonary exercise stress testing equipment is neces-
sary for education in the performance and interpretation of 
this crucial modality in patients with heart failure. Additional 
technology that aids in the diagnosis, risk stratification, and 
management of patients with heart failure, such as echocar-
diography, transesophageal echocardiography, computed 
tomography, magnetic resonance imaging, positron emission 
tomography, invasive angiography, and electrophysiology 
facilities, should be available. Equipment for interrogation 
of implantable electronic devices, including cardiac resyn-
chronization therapy and implantable cardioverter-defibrilla-
tors should be available for both inpatients and outpatients. 
Trainees should have access to catheterization laboratories 
equipped with both thermodilution and Fick-based modali-
ties for measuring cardiac output. Equipment for management 
and interrogation of durable MCS devices (eg, Heartmate, 
HeartWare, or Total Artificial Heart) should be available so 
trainees gain proficiency in their use. When institutionally 
available, temporary, nondurable MCS devices including 
but not limited to intra-aortic balloon pump, TandemHeart, 
Impella devices, and/or extracorporeal membrane oxygen-
ation should be accessible to trainees. It is not expected that 
each institution will have all of these devices, but every center 
should have some. At all facilities, resuscitation equipment 
must be readily accessible.
2.4. Ancillary Support
Level III trainees should communicate with ancillary person-
nel to ensure comprehensive, evidence-based care. Critical 
to success is collaborative interaction with various physi-
cians from within cardiology, including interventionalists, 
advanced imaging specialists, electrophysiologists, congenital 
heart disease specialists, and other fields of general medical 
and surgical practice, to address and treat the multiple comor-
bidities often seen in heart failure patients. Key specialties 
include but are not limited to cardiac and transplant surgeons, 
palliative care practitioners, infectious disease specialists, 
gastroenterologists, hepatologists, nephrologists, pulmonolo-
gists, pulmonary hypertension (PH) specialists, and experts 
in sleep medicine. In addition, communication with primary 
care physicians, geriatricians, obstetricians, endocrinologists, 
and oncologists is important for specific patient populations. 
Also essential is interaction with vital healthcare professionals 
including nurse practitioners and physician assistants, nurses, 
pharmacists, dieticians, physical and occupational therapists, 
and social workers.
3. Training Components
3.1. Didactic Program
Didactic instruction may take place in a variety of formats, 
including lectures, journal clubs, grand rounds, clinical case 
presentations, research conferences, simulator-based train-
ing, and patient safety or quality improvement conferences. 
Discussions should focus on heart failure, PH, MCS, heart 
transplantation, and the medical knowledge items outlined in 
Table 1. Case conferences, in particular, will allow AHFTC 
trainees opportunities to reflect on and learn from complex 
cases, generate ideas for stabilizing or improving patients’ 
health status and systems of care, and develop skills as team 
leaders and educators. Journal clubs bring advances in the 
field to trainees and provide opportunities to critically review 
published literature, including assessments of validity and 
generalizability. Neither the most recent ACGME Program 
Requirements for Graduate Medical Education in AHFTC5 
nor the COCATS 4 Heart Failure report3 specifies the fre-
quency of didactic instruction, but weekly didactic sessions 
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Table 1. Competency Components and Curricular Milestones for Level III Training in Advanced Heart Failure and Transplant Cardiology
Milestones (Months)
Medical Knowledge All12 Add
Heart Failure
  1. Know the principles of excitation-contraction coupling and the contractile apparatus of the cardiomyocyte. x  
  2. Know the pathophysiology of heart failure, including such concepts as ventricular remodeling, neurohormonal activation, 
fetal gene expression, wall stress, signaling pathways (calcium, beta-adrenergic signaling, and nitric oxide), myocardial 
energetics, electrical and mechanical dyssynchrony, and the role of the extracellular matrix.
x  
  3. Know common genetic underpinnings of both dilated and hypertrophic cardiomyopathy, their clinical phenotypes, and the 
role of genetic testing for patients and their families.
x  
  4. Know important hemodynamic principles related to heart failure, including normal cardiac physiology, contractility, preload, 
afterload, and interpretation of pressure-volume loops and ventricular performance (Frank-Starling) curves.
x  
  5. Know the epidemiology and risk determinants of left ventricular dysfunction, ventricular hypertrophy, and heart failure (both 
with reduced and preserved ejection fraction), including incidence and prevalence overall and in special populations.
x  
  6. Know classification methods of heart failure including American College of Cardiology/American Heart Association  
stages, New York Heart Association classes, and INTERMACS (Interagency Registry for Mechanically Assisted Circulatory 
Support) profiles.
x  
  7. Know the risk factors, methods, and risk scores commonly used to stratify patients with heart failure, including their 
limitations, and how these methods are used to evaluate the need for advanced therapies.
x  
  8. Know the epidemiology and pathophysiology of acute systolic or diastolic heart failure, including new-onset and acute-on-
chronic heart failure.
x  
  9. Know typical and atypical clinical presentations of patients with advanced heart failure (eg, cachexia, worsening renal 
function, cognitive impairment, medication intolerance, ventricular tachycardia) and their management.
x  
10. Know the risks of arterial and venous thromboembolic complications in patients with heart failure. x  
11. Know the pathophysiology, clinical presentation, and differential diagnosis of heart failure with preserved ejection fraction 
and its management.
x  
12. Know the pathophysiology, clinical presentation, and methods of risk stratification of patients with hypertrophic 
cardiomyopathy and its management.
x  
13. Know the distinguishing features of and appropriate diagnostic studies for specific etiologies of heart failure, including 
coronary artery disease, valvular heart disease, hypertension, myocarditis, infiltrative processes, toxins (eg, illicit drugs), 
chemotherapy, pregnancy, congenital heart disease, radiation, pericardial processes, endocrinopathies, high-output states, 
stress cardiomyopathy, and inherited syndromes.
x  
14. Know the indications for percutaneous and surgical intervention for valvular heart disease in patients with heart failure. x  
15. Know the evidence base, including randomized clinical trial data, supporting contemporary guideline-directed heart failure 
therapy.
x  
16. Know the pharmacology of common inotropes and vasopressors used in the management of low-output heart failure  
and shock.
x  
17. Know key principles regarding transitions of care between the outpatient and inpatient setting, and vice versa, including 
indications for hospitalization and readiness for discharge for patients with heart failure.
x  
18. Know the role of assays for natriuretic peptide and other biomarkers in the management of patients with heart failure. x  
19. Know the utility of noninvasive imaging (eg, echocardiography, nuclear cardiology, cardiac magnetic resonance imaging, 
and positron emission tomography) in assessment of patients with cardiomyopathy (including those related to valvular heart 
disease) and heart failure.
x  
20. Know the strengths and limitations of common quality-of-life tools (eg, Minnesota Living with Heart Failure and Kansas City 
Cardiomyopathy Questionnaire) used in patients with heart failure.
x  
21. Know which lifestyle choices and comorbidities (eg, obstructive sleep apnea, depression, anemia, diabetes, hypertension, 
renal failure) contribute to the development of or clinical instability of patients with heart failure, as well as potential 
management options for such comorbid conditions.
x  
22. Know the roles of submaximal (including 6-minute walk) and maximal exercise testing, and cardiopulmonary stress testing 
in patients with heart failure.
x  
23. Know the roles of implantable cardiac electronic device therapy in patients with heart failure, including cardioverter-defibrillators, 
pacemakers, and resynchronization devices.
x  
(Continued )
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24. Know the roles of coronary imaging, ischemia testing, viability testing, and revascularization in patients with heart failure. x  
25. Know the role of invasive hemodynamic assessment in patients with decompensated heart failure. x  
26. Know the epidemiology and pathophysiology of the cardiorenal syndrome and its management. x  
27. Know the pathophysiology of cardiac dysfunction associated with cirrhosis and the hemodynamic consequences of portal 
hypertension.
x  
28. Know the role of implantable technology to allow monitoring of patients with heart failure, including from afar (ie, remote 
monitoring).
x  
29. Know the definition of frailty, tools available for assessment of frailty, and how frailty influences diagnosis, prognosis, and 
candidacy for advanced therapies in patients with heart failure.
x  
30. Know the roles of palliative and hospice care in patients with heart failure and the steps needed to implement them. x  
31. Know the role of endomyocardial biopsy in the evaluation of myocarditis and infiltrative cardiomyopathies. x  
32. Know the various chemotherapy agents associated with heart failure and the management of cardiac complications of 
chemotherapy.
x  
33. Know the potential contribution of arrhythmias to development of heart failure and/or decompensation and appropriate 
pharmacological and ablation options for therapy.
x  
34. Know the roles of exercise training and cardiac rehabilitation in patients with heart failure with or without pulmonary 
hypertension, cardiac transplantation, or mechanical circulatory support.
x  
Pulmonary Hypertension
35. Know the World Heart Organization classification and etiologies of pulmonary hypertension. x  
36. Know the epidemiology, risk factors, prognostic factors, and natural history of pulmonary hypertension. x  
37. Know the functional classes and appropriate treatment of patients with each type of pulmonary hypertension. x  
38. Know the role of invasive hemodynamic assessment, including when to perform vasoreactivity testing to assess and 
manage patients with pulmonary hypertension, including pre- and post-capillary components.
x  
39. Know the classes of medications available to treat pulmonary hypertension and their use alone and in combination, 
including management of side effects.
x  
40. Know the roles of exercise and cardiopulmonary testing to assess and manage patients with pulmonary hypertension. x  
41. Know the indications for referral to a specialized pulmonary hypertension center. x  
42. Know the roles of balloon atrial septostomy, thromboendarterectomy, and lung transplantation in patients with pulmonary 
arterial hypertension.
x  
Mechanical Circulatory Support
43. Know indications for and contraindications to both temporary and durable mechanical circulatory support for bridging and 
destination therapy.
x  
44. Know the expected survival following use of durable mechanical circulatory support. x  
45. Know clinical determinants favoring mechanical circulatory support versus transplantation as durable strategies. x  
46. Know optimal anticoagulation strategies for patients with ventricular assist devices. x  
47. Know the management principles for patients with cardiogenic shock, including selection of temporary mechanical 
circulatory support.
x  
48. Know the management principles and potential complications of extracorporeal membrane oxygenation. x  
49. Know the anatomic, surgical, and comorbid conditions that may impact mechanical circulatory support strategies in adult 
patients with congenital heart disease.
x  
50. Know intraoperative and early postoperative complications of durable mechanical circulatory support. x  
51. Know the risk factors for and presentations and management of common complications of durable ventricular assist 
devices, including right heart failure, stroke, driveline infections, device thrombosis, hemolysis, gastrointestinal bleeding, 
and aortic insufficiency.
x  
52. Know the risk scores that predict right heart failure in patients with left ventricular assist devices. x  
(Continued )
Table 1. Continued
Milestones (Months)
Medical Knowledge (continued) All12 Add
Heart Failure (continued)
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Cardiac Transplantation
53. Know the indications for and contraindications to heart transplantation. x  
54. Know when patients listed for heart transplant need mechanical circulatory support, and the potential benefits and 
complications of this type of therapy.
x  
55. Know current United Network for Organ Sharing allocation listing policies for heart transplantation. x  
56. Know the expected short- and long-term survival rates following heart transplantation. x  
57. Know the role of multiorgan (eg, heart-lung, heart-kidney, heart-liver) transplantation. x  
58. Know the principles of immunology that pertain to heart transplantation, including sensitization and histocompatibility. x  
59. Know and understand the efficacy, risks, and limitations of currently available methods for desensitization of patients 
awaiting heart transplantation.
x  
60. Know the preoperative considerations applicable to potential heart transplant recipients. x  
61. Know the anatomic, surgical, and comorbid conditions that may impact transplant surgery planning and outcomes in adult 
patients with congenital heart disease, necessitating evaluation at a transplant center with expertise in these conditions.
 x
62. Know the intraoperative and early postoperative complications of heart transplantation and their management. x  
63. Know the process by which the heart procurement team interacts with teams procuring other organs from donors. x  
64. Know the factors used to assess the suitability of a potential donor heart. x  
65. Know the mechanisms of action, side effects, and potential drug–drug interactions of immunosuppressant drugs. x  
66. Know how cardiac denervation impacts cardiac physiology, including response to exercise and pharmacological agents, 
and clinical manifestations of myocardial ischemia.
x  
67. Know the risk factors for, clinical presentations of, and treatment for hyperacute, acute cellular, and antibody- mediated 
rejection.
x  
68. Know the risk factors, clinical presentation, International Society for Heart & Lung Transplantation grading system, and 
strengths and limitations of diagnostic tools for cardiac allograft vasculopathy.
x  
69. Know when to consider cardiac retransplantation. x  
70. Know common post-transplant complications and how to monitor them in the outpatient setting, including hypertension, 
diabetes, malignancy, renal dysfunction, infection, obesity, and endocrinological and neurological sequelae.
x  
71. Know the strengths and limitations of strategies used to detect and monitor transplant rejection. x  
72. Know the grades of acute cellular and antibody-mediated transplant rejection, based on interpretation of an endomyocardial 
biopsy.
x  
73. Know the clinical presentation of common opportunistic infections in cardiac transplant recipients, as well as the potential 
for donor transmission of infectious organisms.
x  
Evaluation Tools: chart-stimulated recall, direct observation, and in-training examination.
Patient Care and Procedural Skills All12 Add
Heart Failure
  1. Skill to oversee genetic testing of patients with cardiomyopathy, including selection of patients and collaboration with 
genetic counselors.
x  
  2. Skills to optimize therapeutic regimens based on guideline-directed pharmacological and device-based therapies in stable 
patients with heart failure with reduced ejection fraction.
x  
  3. Skill to estimate the jugular venous pressure by clinical examination. x  
  4. Skills to optimize a diuretic regimen in both the inpatient and outpatient settings. x  
  5. Skill to decide whether and when to hospitalize patients with heart failure. x  
  6. Skill to optimize pharmacological therapies in patients with decompensated heart failure, including adjustments after 
stabilization and prior to discharge.
x  
  7. Skills to assess left ventricular systolic and diastolic properties noninvasively in patients with heart failure. x  
  8. Skill to select individualized diagnostic testing for patients with a new diagnosis of heart failure. x  
(Continued )
Table 1. Continued
Milestones (Months)
Medical Knowledge (continued) All12 Add
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  9. Skill to minimize the risk of hospital readmission following discharge for decompensated heart failure. x  
10. Skills to recognize and stabilize patients with cardiogenic shock. x  
11. Skills to recognize and stabilize noncardiogenic shock in patients with cardiomyopathy or a history of heart failure. x  
12. Skills to perform and interpret findings from right heart catheterization in patients with heart failure. x  
13. Skills to assess risk of patients with heart failure undergoing cardiac or noncardiac surgery, and to manage their 
hemodynamic status perioperatively.
x  
14. Skills to perform and interpret cardiopulmonary stress testing. x  
15. Skills to initiate palliative and supportive care and to address symptoms and goals of care for patients with advanced heart 
failure across the care continuum.
x  
16. Skills to manage supraventricular and ventricular arrhythmias in patients with stable or decompensated heart failure. x  
17. Skill to collaborate with cardiac electrophysiologists to stabilize patients with ventricular tachycardia storm complicating 
cardiomyopathy, heart failure, or mechanical circulatory support.
x  
18. Skill to collaborate with cardiac surgeons, interventional cardiologists, or members of a structural heart care team to 
determine whether percutaneous or surgical valve intervention is necessary for patients with heart failure.
x  
19. Skills to work effectively with experts in adult congenital heart disease to assess and manage patients with these 
conditions, including determining when to employ mechanical support or cardiac transplantation.
x  
20. Skill to determine the indications for coronary revascularization in patients with ischemic cardiomyopathy. x  
21. Skills to interrogate implantable cardioverter-defibrillators, cardiac resynchronization pacemakers, and cardiac 
resynchronization-defibrillator devices in patients with cardiomyopathy and/or heart failure to determine the burden of 
arrhythmias, diagnostic information, and basic device functionality.
x  
22. Skill to determine when patients are inotrope-dependent and to manage them in the outpatient setting. x  
23. Skill to work effectively with obstetricians in the care of pregnant patients with a cardiomyopathy and/or heart failure. x  
24. Skill to provide self-help tools to patients with heart failure to minimize the risk of decompensation. x  
25. Skills to educate heart failure patients about warning signs that signify or predict clinical instability, and to help them 
develop action plans in the event warning signs appear.
x  
Pulmonary Hypertension
26. Skill to evaluate patients with pulmonary hypertension to determine etiology. x  
27. Skill to recommend the initial pharmacological regimen for patients with pulmonary arterial hypertension. x  
28. Skills to assess functional capacity and risk stratify patients with pulmonary arterial hypertension. x  
29. Skills to perform serial noninvasive assessments of right ventricular function and pulmonary arterial pressure and integrate 
these data in the management of patients with pulmonary hypertension.
x  
30. Skills to detect clinical deterioration in patients with pulmonary hypertension and adjust treatment accordingly, including 
determining when hospitalization is necessary.
x  
31. Skill to stabilize patients with acute right ventricular failure in the setting of pulmonary hypertension. x  
Mechanical Circulatory Support
32. Skill to identify appropriate options for temporary hemodynamic support for patients in cardiogenic shock. x  
33. Skill to identify appropriate candidates for durable ventricular assist devices. x  
34. Skills to interrogate, interpret, and manipulate pump parameters in patients with temporary and durable hemodynamic 
assist devices.
x  
35. Skill to recognize the indications for total artificial heart or right ventricular assist device rather than left ventricular assist 
device alone.
 x
36. Skill to optimally set the speed of durable ventricular assist devices. x  
37. Skills to select and interpret noninvasive and invasive data to evaluate patients with temporary and durable ventricular 
assist devices (eg, ramp study, aortic valve opening, or right ventricular assessment).
 x
(Continued )
Table 1. Continued
Milestones (Months)
Patient Care and Procedural Skills (continued) All12 Add
Heart Failure (continued)
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38. Skills to identify and manage right heart failure in patients with left ventricular assist devices. x  
39. Skill to manage long-term durable mechanical circulatory support in the outpatient setting. x  
40. Skills to recognize and manage complications of durable mechanical circulatory support, including stroke, device 
thrombosis, right heart failure, hypertension, or arrhythmias.
x  
41. Skills to recognize left ventricular recovery and assess patients with left ventricular assist devices for potential explantation.  x
42. Skill to determine whether and when to hospitalize patients with durable ventricular assist devices. x  
43. Skill to select management options (including hospitalization and diagnostic investigation) for patients with durable 
ventricular assist devices and gastrointestinal bleeding.
x  
44. Skills to collaborate with anesthesiologists and procedural specialists to optimize management during invasive procedures 
or noncardiac surgery in patients with continuous flow, durable ventricular assist devices.
x  
Cardiac Transplantation
45. Skill to determine whether and when patients warrant cardiac transplantation. x  
46. Skill to recognize comorbidities that preclude cardiac transplantation. x  
47. Skill to recognize irreversible pulmonary hypertension that precludes isolated heart transplantation. x  
48. Skill to assess the suitability of a given heart for transplantation in a potential recipient. x  
49. Skills to adjust immunosuppressant therapy to minimize the risk of rejection, while balancing competing risks of infection, 
malignancy, renal failure, and other toxicities.
 x
50. Skill to collaborate with colleagues in the histocompatibility laboratory to assess a heart transplant recipient’s reactive antibody 
panel, preformed and post-transplant antihuman leukocyte antigen antibodies, and immunological compatibility with a donor heart.
x  
51. Skill to manage heart transplant recipients in the immediate post-transplant period, including those with complications, in 
conjunction with a multidisciplinary team.
x  
52. Skill to determine whether and when illness in heart transplant recipients requires hospitalization. x  
53. Skills to interpret with a pathologist the findings of endomyocardial biopsies to determine the need for treatment of acute 
cellular or antibody-mediated rejection, and oversee treatment.
x  
54. Skills to collaborate with other members of a multidisciplinary team in managing common comorbidities and complications 
following heart transplantation, including hypertension, dyslipidemia, renal insufficiency, infection, and cancer.
x  
55. Skills to collaborate with invasive and interventional cardiologists in the prevention, recognition, and treatment of transplant 
vasculopathy.
x  
56. Skills to interpret noninvasive tests, including echocardiograms, gene expression profiling (eg, Allomap testing), and other 
biomarkers to evaluate for rejection in heart transplant recipients.
x  
57. Skill to perform endomyocardial biopsy to assess for transplant rejection. x  
58. Skill to prescribe therapies to prevent opportunistic infections, including Cytomegalovirus, Nocardia, and Pneumocystis 
Jiroveci pneumonia in heart transplant recipients.
x  
59. Skill to oversee the use of immunizations in patients before and after cardiac transplantation. x  
Evaluation Tools: chart-stimulated review, direct observation, and multisource evaluation.
Systems-Based Practice All12 Add
1. Utilize appropriate care settings and teams for patients with various profiles and stages of heart failure before or after 
mechanical circulatory support or transplantation.
x  
2. Incorporate risk/benefit analysis and cost considerations in diagnostic and treatment decisions, including the adoption of 
new technologies.
x  
3. Utilize an interdisciplinary, coordinated team approach for patient management, including care transitions, palliative care, 
and employment-related issues.
x  
4. Effectively utilize an interdisciplinary transitional-care approach to monitor the progress of ambulatory patients with heart 
failure to maintain stability and avoid preventable hospitalization.
x  
5. Collaboratively work with all members of the advanced heart failure and transplant cardiology team, including cardiac 
surgeons, palliative care specialists, other medical consultants, nurses, nurse practitioners, physician assistants, social 
workers, dietitians, physical and occupational therapists, and pharmacists.
x  
(Continued )
Table 1. Continued
Milestones (Months)
Patient Care and Procedural Skills (continued) All12 Add
Mechanical Circulatory Support (continued)
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are a reasonable goal. Moreover, training programs should 
emphasize to AHFTC trainees the importance of lifelong 
learning that does not end upon completion of fellowship. For 
example, trainees should develop the ability to incorporate 
new therapies and technologies into practice.
3.2. Clinical Experience
Level III training in advanced heart failure requires rigorous 
clinical experiences in both the outpatient and inpatient set-
tings, including the intensive care unit. In each clinical setting, 
trainees should participate in supervised patient care and act 
as a first-line consultant for a portion of the training period 
with appropriate and timely backup from attending AHFTC 
physicians. In this capacity, Level III trainees are expected to 
gather accurate, essential information from all sources, includ-
ing medical interviews and record review, physical examina-
tion, cardiac device interrogation, and diagnostic procedures, 
including echocardiograms and hemodynamic evaluations. 
In addition, trainees should issue informed recommenda-
tions about preventive, diagnostic, therapeutic, and palliative 
options and interventions based on clinical judgment, scien-
tific evidence, and patient preferences, ultimately developing, 
negotiating, and implementing patient management plans. 
Further, they should develop the skills necessary to compe-
tently perform the diagnostic and therapeutic procedures con-
sidered essential to the management of patients with advanced 
6. Identify the financial, cultural, social, and emotional barriers to successful outcomes after mechanical circulatory support or 
transplantation.
x  
7. Effectively utilize an interdisciplinary approach to care for patients with or at risk of advanced heart failure, pulmonary 
hypertension, and mechanical circulatory support or cardiac transplantation.
x  
Evaluation Tools: chart-stimulated recall, direct observation, and multisource evaluation.
Practice-Based Learning and Improvement All12 Add
1. Identify knowledge and performance gaps and engage in opportunities to achieve focused education and performance 
improvement.
x  
2. Utilize decision support tools to access guidelines and pharmacological information at the point of care. x  
3. Incorporate feedback from faculty and staff to improve performance. x  
4. Develop habits of regular and critical reading of the heart failure/transplant literature to maintain current knowledge of the 
field and promote lifelong learning.
x  
Evaluation Tools: conference presentation, direct observation, global evaluation, reflection, and self-assessment.
Professionalism All12 Add
1. Show compassion for and effective management of end-of-life issues, including discussions of death and dying, across the 
spectrum of patients with heart failure, pulmonary hypertension, mechanical circulatory support, or heart transplantation.
x  
2. Clearly and objectively discuss available therapies for advanced heart failure, including palliative care, mechanical 
circulatory support, or transplantation.
x  
3. Interact respectfully with patients, families, and all members of the healthcare team, including ancillary and support staff. x  
4. Demonstrate high ethical standards, including the recognition and management of overt and more subtle potential conflicts 
of interest, when making diagnostic or therapeutic decisions.
x  
Evaluation Tools: conference presentation, direct observation, multisource evaluation, reflection, and self-assessment.
Interpersonal and Communication Skills All12 Add
1. Communicate with and educate patients and families across a broad range of cultural, ethnic, and socioeconomic 
backgrounds.
x  
2. Engage in shared decision making, including the potential role of palliative care and discussing the risk of death, with 
patients and their families considering mechanical circulatory support and/or transplant.
x  
3. Effectively lead the interdisciplinary heart failure team to promote comprehensive and balanced decision making with 
respect to the selection of mechanical circulatory support versus heart transplantation.
x  
4. Skill to discuss the potential for donor transmission of infectious agents to the recipient, and ability to use a shared 
decision-making approach with recipients when assessing a donor at risk.
x  
5. Skill to provide emotional support to patients and their families before and after mechanical circulatory support or cardiac 
transplantation.
x  
Evaluation Tools: direct observation and multisource evaluation.
Add = Additional competencies that extend beyond the core expectations and that may be achieved by some advanced heart failure and transplant cardiology (AHFTC) 
specialists based on career focus, either during or following formal AHFTC fellowship training (see text for details).
Table 1. Continued
Milestones (Months)
Systems-Based Practice (continued) All12 Add
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heart failure, including those undergoing MCS or cardiac 
transplantation. Training programs must provide access to a 
patient population of sufficient size and diversity to nurture 
these competencies. Multidisciplinary meetings, including 
participation in the transplant selection committee, are impor-
tant parts of the trainee’s clinical experience.
3.3. Hands-On Procedural Experience
Hands-on experience is required for successful training, and 
trainees should be exposed to the full spectrum of AHFTC 
procedures. Level III training in AHFTC requires competence 
in right heart catheterization and endomyocardial biopsy, 
acquired through experiences in the catheterization labora-
tory. Troubleshooting of right heart catheters in the intensive 
care unit provides additional expertise in the use of invasive 
hemodynamic monitoring, including recognition of artifact. 
Review of endomyocardial biopsy specimens with patholo-
gists facilitates skill in the assessment of rejection. AHFTC 
trainees must become familiar with the programming and 
interpretation of data stored in implantable cardioverter-
defibrillators and cardiac resynchronization therapy devices, 
which can be acquired by device interrogation. Experience in 
the indications and management of MCS devices providing 
temporary hemodynamic support of critically ill patients with 
heart failure is essential, recognizing that criteria for selection 
of specific devices may vary. AHFTC training includes expo-
sure to implantation, interrogation, and adjustment of durable 
ventricular assist devices under echocardiographic guidance. 
Supervision of cardiopulmonary stress tests promotes exper-
tise in this modality. Training should also include end-of-life 
discussions, shared decision making, and communication 
with patients about advance care planning. Depending upon 
institutional capabilities and trainee interest, additional pro-
cedural experiences may include implantation and/or moni-
toring of pulmonary artery sensors, invasive assessment of 
patients with adult congenital heart disease, performance and 
interpretation of the results of pulmonary vasodilator chal-
lenges, assessment of exercise hemodynamics, or implanta-
tion of temporary MCS devices. The numbers of procedures 
that should be completed during the 12 months of AHFTC are 
summarized in Section 4.2, and the approach to evaluation of 
competency is in Section 5.
The field of advanced heart failure is rapidly evolving with 
the introduction of new technologies. Although specific train-
ing requirements cannot be provided for all of these, Level III 
AHFTC trainees who intend to perform these procedures are 
expected to undergo the same training as required for faculty 
members performing them.
3.4. Diagnosis and Management of Emergencies and 
Complications
All trainees should be certified in advanced cardiovascular 
life support and well versed in the recognition and manage-
ment of complications and emergencies encountered in the 
advanced heart failure population. Examples include cardio-
genic shock, such as INTERMACS (Interagency Registry 
for Mechanically Assisted Circulatory Support) 1 patients; 
life-threatening arrhythmias, such as ventricular tachycardia 
storm and complete heart block; severe cardiac complications 
in pregnant patients; respiratory failure in patients with heart 
failure and concomitant pulmonary illness; severe rejection 
with allograft failure; or life-threatening infection in immuno-
suppressed transplant recipients. Complications of endomyo-
cardial biopsy and pulmonary artery catheterization should be 
recognized and managed, with emphasis upon knowing when 
to seek assistance from an interventional cardiologist or car-
diothoracic surgeon in such circumstances as cardiac perfora-
tion or pericardial tamponade. Trainees should be taught to 
recognize and initiate management for complications of MCS 
devices, including thrombosis, stroke, infection, bleeding, and 
pump malfunction. They should be familiar with advanced life 
support in patients receiving mechanical support.6 All such 
complications should be documented and reported in accor-
dance with institutional requirements and reviewed at patient 
safety or quality improvement conferences.
3.5. Diagnosis and Management of Less Common 
Clinical Conditions and Syndromes
Level III trainees should become familiar with less common 
conditions associated with heart failure symptoms. These 
include myocardial noncompaction, hypertrophic cardiomy-
opathy, cardiac amyloidosis, muscular dystrophy, arrhyth-
mogenic right ventricular cardiomyopathy, glycogen storage 
disease, congenital heart defects, sarcoidosis, hemochroma-
tosis, and pulmonary artery hypertension, as well as other 
infectious, nutritional, and autoimmune conditions. Several 
uncommon inflammatory conditions have the potential to 
cause cardiomyopathy and heart failure, including fulminant 
giant cell myocarditis and acute hypersensitivity myocarditis. 
Metabolic or endocrine disorders such as pheochromocytoma 
and acromegaly can lead to cardiomyopathy and heart fail-
ure. Other less common conditions presenting as heart failure 
include cardiac neoplasms, constrictive pericarditis, or acute 
right ventricular failure (RVF). The Level III trainee should be 
aware of these less-common conditions and understand their 
pathophysiology and management. The Level III trainee may 
not be expert in managing these conditions, but should be able 
to stabilize patients with them and seek guidance from the lit-
erature and from experts.
3.6. Research and Scholarly Activity
All trainees are expected to carry out research and/or engage 
in scholarly activities during Level III training in AHFTC. 
Scholarly activity related to heart failure, PH, MCS, or trans-
plant cardiology may include original clinical, basic science, 
translational, or interdisciplinary research; quality improve-
ment activities; presentation at institutional, local, and 
national meetings; and publication of original papers, reviews, 
chapters, or case reports. Trainees should be encouraged to 
develop and maintain habits of self-learning and continuous 
professional improvement by reading heart failure and heart 
transplantation journals and attending journal clubs, confer-
ences, and appropriate scholarly meetings. A trainee’s prog-
ress in research should be monitored by mentors through 
general oversight, direct observation, and critical review of 
presentations and manuscripts.
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4. Training Requirements
4.1. Development and Evaluation of Core 
Competencies
Training requirements in AHFTC address the 6 general com-
petencies promulgated by the ACGME and endorsed by the 
ABIM: medical knowledge, patient care and procedural skills, 
practice-based learning and improvement, systems-based 
practice, interpersonal and communication skills, and pro-
fessionalism. The ACC has used this structure to define and 
depict the components of the clinical competencies for car-
diology. The curricular milestones for each competency and 
domain also provide a developmental roadmap for fellows as 
they progress through various levels of training and serve as 
an underpinning for the milestones reported to ACGME. The 
ACC has adopted this format for its competency and training 
statements, career milestones, lifelong learning, and educa-
tional programs.
Table 1 depicts the 6 competency domains and their asso-
ciated curricular milestones for training in AHFTC, as well 
as examples of evaluation tools suitable for assessing com-
petence in each domain. The focus of this document is on 
delineation of the core competencies expected of all trainees 
in AHFTC upon successful completion of a standard 1-year 
ACGME–accredited AHFTC fellowship. These competencies 
are marked under the column “All.” Certain areas of advanced 
knowledge or procedural skills are not typically encountered 
enough during a standard 12-month period of training to 
develop and demonstrate competence, and therefore, require 
additional dedicated exposure. These selected Level III com-
petency components are designated in the “Add” column of 
the table, usually require additional training, and represent a 
skill level beyond that necessary for AHFTC certification. One 
year of formal training beyond the standard 3-year general 
cardiovascular fellowship, for example, is unlikely to confer 
expert competency in the management of the most complex 
patients undergoing heart transplantation or ventricular assist 
device implantation or those requiring other more specialized 
knowledge or procedural skills. These additional competen-
cies may be obtained during or after the standard AHFTC 
fellowship, depending on the trainee’s career focus and the 
opportunities available at the training program. The milestone 
interval indicates the stage by which the typical trainee will 
have achieved a particular competency. Although the com-
petency components included in the “All” column should be 
achieved by all trainees and are appropriate areas for assess-
ment, not every component needs to be individually assessed 
in every trainee. Rather, as with all educational activities, 
assessment is a sampling process that should be tailored to the 
needs of the individual trainee and program.
4.2. Number of Procedures
An essential component of training an AHFTC practitioner is 
robust understanding of the indications for, contraindications 
to, and complications of procedures commonly performed 
in patients with advanced heart failure, including ventricu-
lar assist devices and cardiac transplantation (Table 2). Each 
trainee should maintain a record that documents the indica-
tions, outcomes, and diagnoses associated with procedures 
Table 2. Recommendations for Minimum Procedural Volume or 
Technical Experience to Achieve and Demonstrate Competence 
in AHFTC
Procedure/Technical Skill Numbers*
Observe and interpret CPX 5 (observe)
20 (interpret)
Perform and interpret right heart 
catheterization
50 (of which at least 30 should 
be pretransplantation)
Perform and interpret pulmonary 
vasodilator challenge in pulmonary 
hypertension†
5
Interrogate ICDs and CRT devices 20/20 (or document 
comparable training during 
general cardiology fellowship 
and review 3 ICD and 3 CRT 
interrogations with an EP 
attending who attests to the 
competency expected of AHFTC 
physicians)
Observe implantation of VADs 3
Perform and interpret VAD interrogation 10
Oversee the medical care, including 
anticoagulation and VAD speed setting, 
of LVAD recipients
15 (of which 5 must be during 
index hospitalization of LVAD 
implantation)
Perform and interpret LVAD ramp 
procedures†
10
Observe procurement of donor organs 3
Observe cardiac transplant surgery 3
Oversee the medical care, including 
immunosuppressive regimen, of a 
cardiac transplant recipient
30 (of which 5 must be during 
index transplant hospitalization)
Perform endomyocardial biopsies, 
femoral access
5
Perform endomyocardial biopsies, 
internal jugular access
45
Review endomyocardial specimens, 
with a range of pathology, in 
collaboration with a pathologist
20
Interpret the severity of CAV from a 
coronary angiogram utilizing the ISHLT 
Cardiac Allograft Vasculopathy Grading 
scale
10
Participate in end-of-life and/or 
palliative care discussions
10
*Recommendations for number of procedures required are based on 
consensus recommendations and indicate numbers that should be performed 
and/or interpreted successfully to achieve competence. These numbers are 
intended as general guidance, based on the educational needs and progress of 
typical AHFTC trainees. Competency to perform each procedure must be based 
on evaluation by the supervising physician and may exceed or be below the 
threshold number shown in Table 2.
†Acquired during additional months beyond a dedicated 12-month advanced 
heart failure/transplant fellowship.
AHFTC = advanced heart failure and transplant cardiology; CAV = cardiac 
allograft vasculopathy; CPX = cardiopulmonary exercise testing; CRT = cardiac 
resynchronization therapy; EP = electrophysiology; ICD = implantable cardioverter-
defibrillator; ISHLT = International Society for Heart & Lung Transplantation; 
LVAD = left ventricular assist device; and VAD = ventricular assist device.
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that he or she performed or attempted, along with the name of 
the supervising faculty member.
It is axiomatic that direct supervision of invasive proce-
dures performed by trainees must occur until the trainee 
demonstrates sufficient proficiency and judgment, attain-
ment of which must be documented by the Program Director. 
Faculty members must teach and supervise trainees in the 
performance and interpretation of procedures. Trainees must 
participate in preprocedural planning and postprocedural 
management.
In addition to the skills to safely perform procedures, the 
trainee must possess the skills to determine the appropriate 
procedure, obtain and interpret procedural data, and utilize the 
data to optimize patient care. The suggested minimum proce-
dural volumes during AHFTC training are shown in Table 2.
4.3. Heart Failure
The AHFTC trainee should know the pathophysiology of heart 
failure at the molecular, cellular, and organ levels, including the 
roles of neurohormonal activation and ventricular remodeling 
in disease progression. They also should know the diagnostic 
and management strategies for patients with heart failure due 
to ischemic and nonischemic forms of heart disease, includ-
ing infiltrative cardiomyopathies, inherited cardiomyopathies, 
and cardiomyopathies related to endocrinopathy, pregnancy, 
chemotherapy and other toxins such as illicit drugs, as well 
as those with adult congenital heart disease.3 Trainees should 
become proficient in the management of both acute and chronic 
heart failure using available pharmacotherapies, and acquire a 
deep understanding of the evidence base developed from ran-
domized trials that underlie guideline-directed therapies.7 They 
should be familiar with the epidemiology, common genetic 
abnormalities, and risk factors for heart failure and know how 
to assess and manage commonly encountered comorbidities in 
patients with heart failure. The AHFTC trainee should develop 
the skills to identify advanced heart failure, direct an evalua-
tion, and determine the appropriateness of patients for cardiac 
transplantation, MCS, or palliative care.3
4.3.1. Inpatient
The AHFTC trainee should learn the pathophysiology and epi-
demiology of various acute heart failure syndromes, including 
coronary ischemia, accelerated hypertension, decompensated 
heart failure, cardiogenic shock, and right heart failure, in 
patients with and without heart transplantation or MCS. As 
the prevalence of heart failure with preserved ejection fraction 
is approximately 50%, trainees should know the pathophysiol-
ogy (eg, impaired diastolic relaxation, myocardial stiffening, 
ventricular-arterial coupling), clinical presentation, differen-
tial diagnosis and management of acute decompensations of 
patients with this type of heart failure. Trainees should also 
become skilled in selection of an optimal diuretic regimen, 
know the role of vasodilator and inotropic therapy, employ 
measures to prevent thromboembolic complications, know 
criteria for discharge of hospitalized patients with heart fail-
ure, and facilitate safe transition to the outpatient setting.
4.3.1.1. Initial Assessment
The AHFTC trainee should rapidly identify patients with heart 
failure in danger of hemodynamic collapse or death and know 
how to stabilize them. A key element of the initial assessment 
is to identify factors that precipitate hospitalization for heart 
failure. In addition, proficiency in obtaining a history and 
performing a physical examination is essential to assessing a 
patient’s hemodynamic profile,8 and this must be integrated 
with hemodynamic and physiological data in patients present-
ing with decompensated heart failure.
4.3.1.2. Hemodynamic Interpretation
Although invasive hemodynamic monitoring is not routinely 
indicated in the management of patients with acute heart 
failure, trainees should become familiar with indications for 
pulmonary artery catheterization as supported by the 2013 
ACC/AHA Guideline for the Management of Heart Failure.7 
Trainees should acquire the skills to troubleshoot pulmonary 
artery catheters in the catheterization laboratory and intensive 
care unit, and to interpret hemodynamic parameters measured 
by this technology, including right atrial pressure, pulmonary 
artery pressure, pulmonary capillary wedge pressure, cardiac 
output and index, and derived variables including pulmonary 
and systemic vascular resistances. Trainees should learn to 
utilize echocardiographically derived estimates of filling pres-
sures and cardiac output to guide therapy.
4.3.1.3. Cardiogenic Shock
The AHFTC trainee should recognize and stabilize patients 
with cardiogenic shock, and distinguish this from other causes 
of shock. Trainees should learn the indications for, contrain-
dications to, and clinical pharmacology of intravenous vaso-
pressor and inotropic agents in patients with advanced heart 
failure, and recognize patients chronically dependent upon 
these agents. Trainees should promptly identify patients with 
refractory cardiogenic shock and assess candidates for tempo-
rary MCS devices in the context of long-term treatment goals 
(implantable ventricular assist devices, explantation after myo-
cardial recovery, heart transplantation, bridging to decision, or 
palliative care). Familiarity with available temporary support 
device is crucial, and trainees should troubleshoot temporary 
MCS devices in conjunction with a multidisciplinary team. 
Trainees should know the role of palliative and hospice care 
in patients with advanced heart failure. Ongoing care should 
address symptom control, psychosocial distress, health-related 
quality of life, end-of-life care, caregiver support, and access 
to evidence-based disease-modifying interventions.
4.3.1.4. Decompensated Heart Failure
Trainees should become proficient in supervising patients 
hospitalized with decompensation of chronic heart failure 
through initial stabilization and optimization of therapy. 
Management issues include optimizing volume status 
through selection of an appropriate diuretic regimen, rec-
ognition of risk factors for the cardiorenal syndrome, 
implementation of inotropic therapy when indicated, con-
siderations in use of renal replacement therapy, conversion 
from intravenous to oral diuretic medications, and initia-
tion or modification of guideline-directed medical therapy 
during the hospitalization and at discharge. Trainees 
should become facile with other aspects of management 
that may arise during hospitalization, including treatment 
of arrhythmias, interrogation of implantable cardioverter-
defibrillators or cardiac resynchronization therapy devices 
D
ow
nloaded from
 http://ahajournals.org by on August 14, 2019
15  Jessup et al  2017 ACC/AHA/HFSA/ISHLT/ACP Advanced HF and Transplant Cardiology ATS
to determine arrhythmia burden and functionality of the 
device, and assessment of the role of coronary revascular-
ization. Trainees should be able to identify patients whose 
clinical course is on a downward trajectory, including those 
who should receive MCS, cardiac transplantation, or end-
of-life care. Trainees should become proficient in facili-
tating safe transitions of outpatient care that minimize the 
likelihood of readmission for heart failure.
4.3.2. Outpatient
Trainees should learn the various methods of classifying heart 
failure, including the ACC/AHA stages, New York Heart 
Association functional classes, and INTERMACS profiles, as 
well as the epidemiology and risk determinants applicable to 
patients with heart failure with reduced and preserved ejec-
tion fraction. The AHFTC trainee should learn how to direct 
the outpatient evaluation of patients with recently identified 
heart failure to identify specific etiologies and understand the 
role of genetic testing. Various tools are available to assess 
patients with heart failure, including the clinical history and 
physical examination, multimarker risk scores, quality of life 
assessments, natriuretic peptide testing, stress testing includ-
ing cardiopulmonary stress tests, and noninvasive imaging 
techniques. Trainees should become comfortable with each 
of these modalities and know their strengths and limitations. 
Trainees should learn how to up-titrate guideline-directed 
medical therapy to achieve appropriate targets. Clinical dete-
rioration in an outpatient and indications for hospitalization 
should be recognized. Trainees should learn how to incorpo-
rate advanced care planning and end-of-life discussions in the 
outpatient setting.
4.4. Pulmonary Hypertension
PH treatment involves important elements of hemodynamic 
management of pulmonary artery pressures and right heart 
failure. The AHFTC trainee should be able to manage, or co-
manage with a PH care team, patients with PH from class I to 
advanced class IV stages.
4.4.1. Inpatient
AHFTC trainees should learn how to detect clinical dete-
rioration in hospitalized patients with PH, adjust treatment 
accordingly, and stabilize those with acute RVF using paren-
teral therapies in conjunction with a multidisciplinary team. 
Further, they should learn the appropriate use of invasive 
hemodynamic monitoring and know when to refer patients to 
a PH specialist.
4.4.2. Outpatient
In coordination with a PH care team, the AHFTC trainee 
should learn to classify patients according to the World Heart 
Organization criteria regarding etiology, risk-stratify patients 
with respect to treatment requirements, understand the role 
of exercise testing, and initiate guideline-based therapy for 
patients with PH, cognizant of the pharmacological options 
for PH, including combination therapies and their side effects. 
The trainee should recognize clinical worsening, adjust treat-
ment as necessary, and appropriately refer patients for more 
advanced PH care, including balloon atrial septostomy or lung 
transplantation.
4.5. Mechanical Circulatory Support
A much broader group of individuals will seek competency in 
advanced heart failure cardiology than will directly manage 
patients with durable left ventricular assist devices (LVADs) 
on a daily basis. Nevertheless, MCS is an important therapeu-
tic option for patients with advanced heart failure, including 
those with cardiogenic shock, and all AHFTC trainees should 
acquire competency in the use of these technologies. Trainees 
should understand the results of relevant clinical trials and 
registry data, maintain currency on contemporary guidelines 
for management of patients with mechanical support,9–11 and 
keep abreast of emerging MCS technologies. It is essential 
that trainees learn to identify appropriate candidates for tem-
porary hemodynamic support and durable ventricular assist 
devices. Trainees should appreciate the value of a multidis-
ciplinary team approach to MCS by fostering collaborative 
relationships with cardiac surgeons, intensivists, advanced 
practice providers, social workers, infectious disease special-
ists, palliative care specialists, ventricular assist device coor-
dinators, and other team members.
4.5.1. Inpatient
The trainee must acquire the medical knowledge and clini-
cal skills to identify candidates for temporary and/or durable 
MCS, including those needing biventricular support. The 
trainees should know the indications for and contraindications 
to temporary hemodynamic support, be able to troubleshoot 
devices used in their institution, and develop skills to manage 
patients in the early post-implant period in conjunction with 
the multidisciplinary team.
Patients on durable LVAD support may present with a 
variety of complications. These complications include RVF, 
gastrointestinal bleeding, driveline infections, arrhythmias, 
pump thrombosis, and aortic insufficiency. The trainee should 
know and recognize risk factors for these complications, and 
understand how to manage them. Because early RVF portends 
a poor prognosis following LVAD implantation, the trainee 
should recognize preoperative risk factors for RVF, understand 
perioperative management strategies aimed at minimizing risk 
of RVF, and appreciate circumstances in which biventricular 
support or transplant may be indicated. The trainee should 
master the skills necessary to manage RVF that develops 
after LVAD deployment. The skillset must also include: 1) 
understanding of durable LVAD device parameters and how 
to interpret or manipulate changes in these parameters in clini-
cal context; 2) management of anticoagulation; 3) recognition 
and management of pump thrombosis; 4) development of pro-
fessional rapport with surgical, gastrointestinal, and infectious 
disease colleagues, all of whom play an integral role in help-
ing to manage LVAD complications; and 5) management of 
patients facing imminent death, including relief of symptoms. 
Interested trainees should develop the abilities to perform and 
interpret ramp echocardiograms to assess likelihood of LVAD 
thrombosis, although these skills may require additional train-
ing beyond the typical 12-month AHFTC fellowship.
Finally, because failure to communicate openly and fully 
with patients and caregivers may contribute to unrealistic 
expectations or unmet needs for care, the trainee should mas-
ter the ability to communicate effectively regarding prognosis, 
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level of understanding, and end-of-life preferences, and foster 
a close working relationship with palliative care specialists.
4.5.2. Outpatient
Patients supported with durable ventricular assist devices 
require frequent monitoring in the outpatient setting. The 
trainee should develop the skills to manage patients in this set-
ting, including: 1) optimal titration of pharmacotherapies for 
heart failure, hypertension, and anticoagulation; 2) diagnostic 
interrogation of device-specific pump parameters to inform 
therapy, including optimization of LVAD speed; 3) identifica-
tion of complications that require hospital admission; and 4) 
recognition of patients with left ventricular recovery who may 
benefit from device explantation.
4.6. Cardiac Transplantation
The 12 additional months of an AHFTC fellowship required 
for Level III training may not provide the experience in cardiac 
transplantation required for qualification as a heart transplant 
physician under United Network for Organ Sharing criteria.12 A 
broader group of individuals will seek competency in advanced 
heart failure cardiology than will directly manage patients under-
going cardiac transplantation. Nonetheless, many programs 
offer an experience within the Level III curriculum to establish 
competency in the care of patients undergoing transplantation 
that meets the United Network for Organ Sharing criteria.
Most importantly, through interaction with a wide variety 
of patients at different stages in the transplant process, with 
different levels of acuity, socioeconomic and cultural back-
grounds, healthcare knowledge, and preferences, the trainee 
will acquire necessary competence and expertise in pretrans-
plant and post-transplant management, as outlined in the com-
petency milestones (Table 1).
4.6.1. Inpatient
4.6.1.1. Pretransplant Management
Trainees must learn the approach to recipient selection, 
focusing on identification of candidates ill enough to merit 
transplantation yet free of medical or psychosocial contrain-
dications,13 and also know how to evaluate the quality of a 
potential donor heart. Trainees should learn United Network 
for Organ Sharing allocation listing policies, including when 
to apply for exception for candidates who do not meet stated 
criteria for a given status yet have a comparable severity of ill-
ness. Trainees should become familiar with the management 
of the sensitized patient, including interpretation of panel 
reactive antibodies, and understand desensitization regimens, 
including but not limited to plasmapheresis, intravenous 
immune globulin, rituximab, and bortezomib. Trainees should 
be exposed to the unique issues involved in considering trans-
plantation for patients with adult congenital heart disease.
4.6.1.2. Acute Postoperative Management
The postoperative management of heart transplant recipients 
starts with donor evaluation and organ procurement. Trainees 
should become familiar with the logistics of these steps and 
gain experience interpreting virtual, prospective, and retro-
spective cross-matches; determining the need for induction 
therapy; and managing initial post-transplant immunosup-
pression and infection prophylaxis.
4.6.1.3. Postoperative Complications
Trainees should become familiar with early postoperative 
hemodynamics and be able to direct subsequent testing to 
distinguish such complications as primary graft dysfunction, 
delayed hyperacute rejection, right heart failure related to PH, 
and cardiac tamponade. They should become competent as 
part of a multidisciplinary team in caring for patients requir-
ing temporary mechanical support such as extracorporeal 
membrane oxygenation. Trainees should develop the skills to 
manage potential donor-derived infections and malignancies, 
including informing patients and families of these events, and 
appropriately consult specialists for further evaluation and 
management. Trainees should be able to manage other com-
mon complications in the early postoperative setting, includ-
ing early rejection, bradyarrhythmias and tachyarrhythmias, 
thromboembolism, delirium, and infections.
4.6.1.4. Inpatient Heart Transplant Management Following 
the Index Admission
Heart transplant patients may be readmitted months or years 
after transplantation for cardiac or noncardiac problems, 
such as acute cellular or antibody-mediated rejection, graft 
failure, transplant vasculopathy, infections, or malignancy. 
Trainees will be exposed to heart transplant recipients with 
these complications and should acquire the skills to direct 
the care of such patients. Trainees should collaborate with 
cardiac pathologists interpreting biopsies, interventional car-
diologists considering percutaneous intervention, and infec-
tious disease specialists treating opportunistic infections.14
 
Given that the side effects and toxicities of immunosuppres-
sion affect many organ systems, the AHFTC trainee will con-
sult with numerous other specialists as well. It is particularly 
important for trainees to learn the extracardiac toxicities of 
immunosuppression, such as the neurotoxicity and nephro-
toxicity of calcineurin inhibitors, pulmonary toxicity of pro-
liferation signal inhibitors, and gastrointestinal toxicity of 
mycophenolate mofetil, as patients will likely present symp-
toms of these conditions initially to the AHFTC specialist.15
4.6.2. Outpatient
4.6.2.1. Immunosuppression
The major goal of outpatient management of a heart transplant 
recipient is to maximize benefit and minimize toxicity of immu-
nosuppression. Level III trainees should become familiar with 
strategies to individualize immunosuppression based on the 
patient’s risk of rejection and infection, as guided by a history 
of rejection or infection, medication tolerance, antibody sensiti-
zation, compliance, presence of transplant vasculopathy, malig-
nancy, peripheral blood gene-expression profiling, and results of 
T-cell immune function assays. They should learn the role of stan-
dard triple-drug immunosuppression with a calcineurin inhibitor, 
an antimetabolite (most commonly mycophenolate mofetil), and 
corticosteroids, and know when to consider proliferation signal 
inhibitors sirolimus or everolimus. Trainees should become famil-
iar with methodologies for rejection surveillance and adjunc-
tive immunotherapies for patients with recurrent rejection.
4.6.2.2. Chronic Complications
Chronic immunosuppression places patients at risk of hyper-
tension, obesity, drug-drug interactions, renal dysfunction, 
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gout, diabetes, dyslipidemia, osteoporosis, infections, malig-
nancy, and other disorders. Thus, trainees should learn 
appropriate screening and prevention strategies, including 
immunization, and develop the skills to manage complications 
in conjunction with other providers. Long-term care of heart 
transplant recipients includes screening for and management 
of transplant vasculopathy. Trainees should learn the appropri-
ate triage to revascularization, retransplantation, or end-of-life 
management.
4.7. Shared Decision Making and Palliative Care
According to the ACCF/AHA Guideline for the Management 
of Heart Failure, “palliative and supportive care is effective 
for patients with symptomatic heart failure to improve qual-
ity of life”.7 Furthermore, given the acuity of illness to which 
patients with heart failure are prone, trainees require advanced 
communication skills to care for critically ill patients and 
those with complications following LVAD implantation or 
cardiac transplantation. Trainees should incorporate pallia-
tive care throughout the spectrum of illness and know when 
to consult palliative care specialists. Discussions focused on 
shared decision making provide patients, families, and pro-
viders opportunities to work together to make decisions about 
care and choose treatment options that are aligned with the 
patient’s values, goals, and preferences.16 For example, train-
ees should acquire experience re-evaluating and revising the 
medical regimen and modify device-based therapy as goals of 
care change toward the end of life.
5. Evaluation of Proficiency
Evaluation tools in AHFTC training include direct obser-
vation by instructors, case logbooks, conference and case 
presentations, multisource evaluations, trainee portfolio/
curriculum vitae, in-training examination, and simulation. 
Self-assessment programs are available through the ACC 
and Heart Failure Society of America. Program directors and 
trainees are encouraged to incorporate these resources into the 
course of training. Following completion of AHFTC training, 
trainees will be eligible to take the ABIM Board Certification 
Examination in AHFTC.
Judgement, case management, and bedside and procedural 
skills must be evaluated regularly in every trainee. Quality 
of care and follow-up; reliability; judgement or decisions or 
actions that result in complications; interaction with other phy-
sicians, patients, and laboratory support staff; initiative; and the 
ability to make appropriate decisions independently should be 
considered. Trainees should maintain records of participation 
and advancement in the form of a Health Insurance Portability 
and Accountability Act–compliant electronic database or log-
book that meets ACGME reporting standards and summarizes 
pertinent clinical information (number of cases, diagnoses, dis-
ease severity, outcomes, and disposition for each encounter).
Under the guidance of the program director, faculty should 
verify and document each trainee’s experiences, assess per-
formance, and confirm satisfactory achievement. The pro-
gram director is responsible for confirming experience and 
competence and reviewing the overall progress of individual 
trainees with the Clinical Competency Committee to ensure 
achievement of selected training milestones and identify areas 
in which additional focused training may be required.
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